Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer

被引:1
作者
Garcia, Ainhoa [1 ,2 ]
Torres-Ruiz, Sandra [2 ]
Vila, Laura [2 ]
Villarroel-Vicente, Carlos [1 ,2 ]
Bernabeu, Alvaro [1 ]
Eroles, Pilar [2 ,3 ,4 ]
Cabedo, Nuria [1 ,2 ]
Cortes, Diego [1 ]
机构
[1] Univ Valencia, Dept Pharmacol, Valencia 46100, Spain
[2] Univ Clin Hosp Valencia, Inst Hlth Res INCLIVA, Valencia 46010, Spain
[3] Univ Valencia, Dept Physiol, Valencia 46010, Spain
[4] Ctr Biomed Network Res Canc CIBERONC, Madrid 28019, Spain
来源
RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 11期
关键词
DRUG DISCOVERY; APOPTOSIS; GENISTEIN; FAMILY; INHIBITORS; ESTROGEN; PATHWAY;
D O I
10.1039/d3md00385j
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthesis of three series of 2-aminopropyl derivatives containing a benzopyran nucleus was performed to evaluate their performance against triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-436) and normal breast epithelial cells (MCF10A). For the three series, the cytotoxic activity was as follows: N-methylated derivatives (tertiary amines) 5b, 6b, and 7b > secondary amine benzopyrans 5, 6, and 7 > quaternary amine salts 5c, 6c, and 7c > free phenolic derivatives 5a, 6a, and 7a. The structure-activity relationship showed the importance of the presence of an amine group and a p-fluorobenzyloxy substituent in the chromanol ring (IC50 values from 1.5 mu M to 58.4 mu M). In addition, 5a, 5b, 6a, and 7b displayed slight selectivity towards tumor cells. Compounds 5, 5a, 5b, 6, 6a, 6c, 7, and 7b showed apoptotic/necrotic effects due to, at least in part, an increase in reactive oxygen species generation, whereas 5b, 5c, 6b, 7a, and 7c caused cell cycle arrest in the G1 phase. Further cell-based mechanistic studies revealed that 5a, 6a, and 7b, which were the most promising compounds, downregulated the expression of Bcl-2, while 5b downregulated the expression of cyclins CCND1 and CCND2. Therefore, 2-aminopropyl benzopyran derivatives emerge as new hits and potential leads for developing useful agents against breast cancer.
引用
收藏
页码:2327 / 2341
页数:15
相关论文
共 50 条
  • [31] NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer
    Nagamatsu, Iori
    Onishi, Hideya
    Matsushita, Shojiro
    Kubo, Makoto
    Kai, Masaya
    Imaizumi, Akira
    Nakano, Kenji
    Hattori, Masami
    Oda, Yoshinao
    Tanaka, Masao
    Katano, Mitsuo
    ANTICANCER RESEARCH, 2014, 34 (1A) : 69 - 80
  • [32] Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer
    Kwon, Ahreum
    Lee, Gwi Bin
    Park, Taein
    Lee, Jung Hoon
    Ko, Panseon
    You, Eunae
    Ahn, Jin Hee
    Eom, Soo Hyun
    Rhee, Sangmyung
    Song, Woo Keun
    BIOMEDICINES, 2020, 8 (09)
  • [33] Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer
    He, Jia
    Wang, Luzhen
    Mi, DaZhao
    Guan, Tian
    Liu, Wenjing
    He, Peng
    Gu, Haijun
    Li, Yuzhan
    Peng, Yangrui
    Jia, Ai-Qun
    Chen, Ceshi
    Chen, Yihua
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (11) : 7421 - 7437
  • [34] Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer
    Telang, Nitin T.
    Nair, Hareesh B.
    Wong, George Y. C.
    PHARMACEUTICALS, 2021, 14 (12)
  • [35] HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer
    Mansoori, Behzad
    Terp, Mikkel Green
    Mohammadi, Ali
    Pedersen, Christina Bog
    Ditzel, Henrik Jorn
    Baradaran, Behzad
    Gjerstorff, Morten Frier
    CANCERS, 2021, 13 (20)
  • [36] TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
    Bhola, Neil E.
    Balko, Justin M.
    Dugger, Teresa C.
    Kuba, Maria Gabriela
    Sanchez, Violeta
    Sanders, Melinda
    Stanford, Jamie
    Cook, Rebecca S.
    Arteaga, Carlos L.
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (03) : 1348 - 1358
  • [37] Cytotoxic activity of Cape Fynbos against triple-negative breast cancer cell line
    Adu-Amankwaah, Francis
    Tapfuma, Kudzanai Ian
    Hussan, Raeesa Hoosen
    Tshililo, Ndivhuwo
    Baatjies, Lucinda
    Masiphephethu, Maano Valerie
    Mabasa, Lawrence
    Mavumengwana, Vuyo
    SOUTH AFRICAN JOURNAL OF BOTANY, 2022, 150 : 702 - 710
  • [38] Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells
    Calahorra, Jesus
    Blaya-Canovas, Jose L.
    Castellini-Perez, Olivia
    Aparicio-Puerta, Ernesto
    Cives-Losada, Candela
    Marin, Jose J. G.
    Rementeria, Markel
    Cara, Francisca E.
    Lopez-Tejada, Araceli
    Grinan-Lison, Carmen
    Aulicino, Francesco
    Berger, Imre
    Marchal, Juan A.
    Delgado-Almenta, Violeta
    Granados-Principal, Sergio
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [39] Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
    Lothstein, Leonard
    Soberman, Judith
    Parke, Deanna
    Gandhi, Jatin
    Sweatman, Trevor
    Seagroves, Tiffany
    ONCOLOGY RESEARCH, 2020, 28 (05) : 451 - 465
  • [40] Anticancer activity of palladium-based complexes against triple-negative breast cancer
    Vojtek, Martin
    Marques, Maria P. M.
    Ferreira, Isabel M. P. L. V. O.
    Mota-Filipe, Helder
    Diniz, Carmen
    DRUG DISCOVERY TODAY, 2019, 24 (04) : 1044 - 1058